Managed Healthcare Executive December 4, 2023
Denise Myshko

A recent study has found that FDA inspections of drug manufacturing facilities have increased since the COVID-19 health emergency but have not yet returned to pre-pandemic numbers.

The COVID-19 pandemic impacted the FDA’s ability to properly inspect facilities that manufacture prescription drugs, which could have impacted drug quality, suggests a new paper in the December 2023 issue of Health Economics. Even now after the public health emergency has lifted, the authors said concerns about drug quality remain as regulators work through their backlog of inspections, especially in foreign facilities.

Prescription drug manufacturing outside the United States plays a critical role in the U.S. supply of medications, with India, China and Italy playing a lead role in manufacturing active ingredients.

During...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech, Survey / Study, Trends
FDA issues flu vaccine recommendations: 5 respiratory updates
5 Digital Health Areas To Be Impacted By The FDA Layoffs
FDA Approves First Biosimilar to Omalizumab
Trump's Nominees to Run FDA, NIH Get Greenlighted by Senate Committee
FDA Debuts a New Communications and Compliance Tool for Device Data Integrity Concerns

Share This Article